Bonesupport Holding Gelecekteki Büyüme
Future kriter kontrolleri 6/6
Bonesupport Holding kazanç ve gelirin sırasıyla yıllık 34.5% ve 23.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 46.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 35.9% olacağı tahmin edilmektedir.
Anahtar bilgiler
34.5%
Kazanç büyüme oranı
46.56%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 33.4% |
| Gelir büyüme oranı | 23.7% |
| Gelecekteki özkaynak getirisi | 35.93% |
| Analist kapsamı | Good |
| Son güncelleme | 20 May 2026 |
Gelecekteki son büyüme güncellemeleri
Analiz Makalesi • Apr 25
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
Bonesupport Holding AB (publ) ( STO:BONEX ) missed earnings with its latest first-quarter results, disappointing...Analiz Makalesi • Oct 28
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
It's shaping up to be a tough period for Bonesupport Holding AB (publ) ( STO:BONEX ), which a week ago released some...Recent updates
Anlatı Güncellemesi • May 13
BONEX: Infection Study Outcomes And Segment Focus Will Drive Future Upside
Analysts have kept their SEK price target for Bonesupport Holding broadly steady, with only minor model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions guiding this latest narrative update. What's in the News Bonesupport Holding plans an analyst and investor day focused on how its segment based approach is intended to increase penetration and market share for CERAMENT in prioritized indication areas.Analiz Makalesi • Apr 25
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
Bonesupport Holding AB (publ) ( STO:BONEX ) missed earnings with its latest first-quarter results, disappointing...Anlatı Güncellemesi • Apr 23
BONEX: Clinical Pilot Infection Outcomes Will Support Future Upside Potential
Analysts have raised their price target for Bonesupport Holding by about SEK 10.60 to SEK 377.17, citing updated assumptions that include a slightly higher discount rate, adjusted revenue growth expectations, a revised profit margin outlook, and a lower future P/E multiple. What's in the News Bonesupport Holding announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma.Anlatı Güncellemesi • Apr 07
BONEX: Clinical Pilot Outcomes And 2026 Sales Outlook Will Support Future Upside Potential
Analysts have revised their price target on Bonesupport Holding to SEK 366.6. The update reflects an unchanged fair value along with adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Publication of a US clinical pilot study in OTA International highlighting surgical technique and outcomes for CERAMENT G in trauma cases, providing practical, real world guidance for clinicians considering the product in fracture related infections and osteomyelitis (Key Developments).Anlatı Güncellemesi • Mar 24
BONEX: Clinical Pilot Outcomes And 2025 Guidance Will Support Future Upside Potential
Analysts have kept their SEK price target for Bonesupport Holding unchanged at SEK 366.60, citing broadly consistent assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these factors support a steady valuation view.
Yeni Anlatı • Mar 12
Slow Trauma Center Adoption And Regulatory Hurdles Will Eventually Support A Healthier Business Mix
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products used to treat complex bone infections and defects. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Mar 10
BONEX: Clinical Pilot Results And Strong Guidance Will Support Long-Term Upside Potential
Analysts have trimmed their price target on Bonesupport Holding by SEK 4 to SEK 366.6. This reflects updated assumptions around discount rates, revenue growth and profitability, while keeping future P/E expectations broadly in line with previous views. What's in the News Bonesupport announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma, giving clinicians practical, real world insights into its use in trauma cases.
Yeni Anlatı • Feb 25
US Trauma Expansion And New Surgical Uses Will Transform This Bone Regeneration Specialist
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products such as CERAMENT G and CERAMENT V, for use in complex bone infections and orthopedic procedures. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Feb 23
BONEX: De Novo Shift Will Support Long Term Upside Potential
Analysts have slightly trimmed their fair value estimate for Bonesupport Holding to SEK370.6, from SEK374.6, reflecting minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions, while keeping the overall thesis broadly intact. What's in the News Bonesupport issued earnings guidance for Q4 2025, with net sales expected at 313 MSEK at constant exchange rates, based on company guidance for that period (company guidance).Analiz Makalesi • Feb 12
Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?
Key Insights Bonesupport Holding's estimated fair value is kr293 based on 2 Stage Free Cash Flow to Equity Current...Anlatı Güncellemesi • Feb 08
BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential
Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK374.60 per share. The latest price target update mainly reflects small technical tweaks to the discount rate and future P/E assumptions rather than a shift in the core outlook.Anlatı Güncellemesi • Jan 22
BONEX: De Novo Review Shift Will Support Long Term Upside Potential
Analysts have trimmed their price target for Bonesupport Holding to SEK 374.60 from SEK 391.20, citing slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple. What's in the News Bonesupport Holding issued earnings guidance for the fourth quarter of 2025 with net sales expected at SEK 313 M, based on constant exchange rates (Corporate guidance).Anlatı Güncellemesi • Jan 07
BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential
Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK391.20, with only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This suggests their overall view on the company’s long term potential is essentially unchanged.Anlatı Güncellemesi • Dec 24
BONEX: De Novo Pathway Shift Will Support Strong Future Market Position
Analysts have modestly raised their price target on Bonesupport Holding, citing a slightly lower discount rate and improved visibility into sustaining approximately 38 percent revenue growth and robust 31 percent profit margins. Together, these factors support a fair value of SEK 391.20 per share.Anlatı Güncellemesi • Dec 10
BONEX: Hip Infection Study Success Will Drive Stronger Future Clinical And Market Position
Analysts have modestly raised their price target on Bonesupport Holding to SEK 391.2 per share from SEK 391.2 per share, reflecting largely unchanged long term assumptions on the discount rate, revenue growth, profit margins and future valuation multiples. What's in the News Positive top line data from the CeraHip clinical study show that CERAMENT G enabled successful single stage revision surgery for periprosthetic joint infection of the hip, with no re infections reported over 24 months of follow up (Key Developments).Anlatı Güncellemesi • Nov 25
BONEX: Positive Study Results Will Support Improvements In Hip Infection Outcomes
Analysts have adjusted their price target for Bonesupport Holding, maintaining it at SEK 391.20. Recent evaluations indicate steady expectations in light of updated discount rates and continued confidence in the company's growth and profitability outlook.Analiz Makalesi • Nov 22
Bonesupport Holding AB (publ) (STO:BONEX) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
To the annoyance of some shareholders, Bonesupport Holding AB (publ) ( STO:BONEX ) shares are down a considerable 25...Anlatı Güncellemesi • Nov 07
BONEX: Clinical Study Results Will Drive Long-Term Patient Outcome Improvements
Bonesupport Holding's analyst price target has been updated downward from SEK 401.80 to SEK 391.20, as analysts factor in slightly softer revenue growth forecasts and a higher discount rate. What's in the News Bonesupport announced positive results from a clinical study showing significantly improved patient-reported outcomes for CERAMENT G in single-stage revision surgery for periprosthetic joint infection of the hip (Key Developments).Analiz Makalesi • Oct 28
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
It's shaping up to be a tough period for Bonesupport Holding AB (publ) ( STO:BONEX ), which a week ago released some...Anlatı Güncellemesi • Oct 24
Positive Clinical Results And US Launch Will Drive Future Success
Analysts have revised their price target for Bonesupport Holding from SEK 419.75 to SEK 401.80. This change reflects adjustments to growth and profitability assumptions.Analiz Makalesi • Aug 25
Bonesupport Holding AB (publ)'s (STO:BONEX) Shares May Have Run Too Fast Too Soon
Bonesupport Holding AB (publ)'s ( STO:BONEX ) price-to-sales (or "P/S") ratio of 18.3x might make it look like a sell...Analiz Makalesi • Jul 23
Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear
Bonesupport Holding AB (publ)'s ( STO:BONEX ) recent soft profit numbers didn't appear to worry shareholders, as the...Analiz Makalesi • Jun 28
Bonesupport Holding AB (publ)'s (STO:BONEX) Intrinsic Value Is Potentially 80% Above Its Share Price
Key Insights The projected fair value for Bonesupport Holding is kr508 based on 2 Stage Free Cash Flow to Equity...Analiz Makalesi • Apr 28
Analyst Estimates: Here's What Brokers Think Of Bonesupport Holding AB (publ) (STO:BONEX) After Its First-Quarter Report
It's been a good week for Bonesupport Holding AB (publ) ( STO:BONEX ) shareholders, because the company has just...
Yeni Anlatı • Mar 19
CERAMENT G's US Launch And CERAMENT V's FDA Submission Will Expand Global Presence
CERAMENT G's rapid U.S. penetration addresses a significant market need, likely causing notable revenue growth due to its strong clinical backing.Analiz Makalesi • Mar 01
kr445 - That's What Analysts Think Bonesupport Holding AB (publ) (STO:BONEX) Is Worth After These Results
Shareholders of Bonesupport Holding AB (publ) ( STO:BONEX ) will be pleased this week, given that the stock price is up...Analiz Makalesi • Oct 31
Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders
The market wasn't impressed with the soft earnings from Bonesupport Holding AB (publ) ( STO:BONEX ) recently. Our...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 2,627 | 749 | 611 | 626 | 5 |
| 12/31/2027 | 1,977 | 492 | 382 | 392 | 6 |
| 12/31/2026 | 1,481 | 307 | 283 | 292 | 5 |
| 3/31/2026 | 1,215 | 185 | 244 | 250 | N/A |
| 12/31/2025 | 1,175 | 142 | 216 | 221 | N/A |
| 9/30/2025 | 1,119 | 152 | 235 | 241 | N/A |
| 6/30/2025 | 1,062 | 148 | 207 | 212 | N/A |
| 3/31/2025 | 998 | 122 | 91 | 95 | N/A |
| 12/31/2024 | 899 | 134 | 60 | 66 | N/A |
| 9/30/2024 | 814 | 91 | -3 | 5 | N/A |
| 6/30/2024 | 735 | 289 | -29 | -21 | N/A |
| 3/31/2024 | 656 | 267 | 0 | 7 | N/A |
| 12/31/2023 | 591 | 245 | -24 | -18 | N/A |
| 9/30/2023 | 522 | 214 | -40 | -37 | N/A |
| 6/30/2023 | 448 | -30 | -66 | -63 | N/A |
| 3/31/2023 | 382 | -51 | -51 | -48 | N/A |
| 12/31/2022 | 329 | -68 | -50 | -47 | N/A |
| 9/30/2022 | 287 | -72 | -62 | -58 | N/A |
| 6/30/2022 | 257 | -71 | -72 | -68 | N/A |
| 3/31/2022 | 234 | -82 | -81 | -77 | N/A |
| 12/31/2021 | 213 | -86 | -87 | -83 | N/A |
| 9/30/2021 | 205 | -88 | -90 | -88 | N/A |
| 6/30/2021 | 198 | -96 | -89 | -87 | N/A |
| 3/31/2021 | 182 | -92 | -88 | -86 | N/A |
| 12/31/2020 | 181 | -101 | -103 | -100 | N/A |
| 9/30/2020 | 174 | -115 | -121 | -117 | N/A |
| 6/30/2020 | 165 | -127 | -143 | -139 | N/A |
| 3/31/2020 | 166 | -151 | -155 | -150 | N/A |
| 12/31/2019 | 155 | -161 | N/A | -164 | N/A |
| 9/30/2019 | 132 | -166 | N/A | -176 | N/A |
| 6/30/2019 | 108 | -191 | N/A | -189 | N/A |
| 3/31/2019 | 98 | -182 | N/A | -177 | N/A |
| 12/31/2018 | 97 | -176 | N/A | -172 | N/A |
| 9/30/2018 | 101 | -182 | N/A | -147 | N/A |
| 6/30/2018 | 119 | -146 | N/A | -128 | N/A |
| 3/31/2018 | 128 | -132 | N/A | -112 | N/A |
| 12/31/2017 | 129 | -129 | N/A | -108 | N/A |
| 9/30/2017 | 132 | -112 | N/A | -112 | N/A |
| 6/30/2017 | 126 | -124 | N/A | -106 | N/A |
| 3/31/2017 | 114 | -124 | N/A | -103 | N/A |
| 12/31/2016 | 105 | -110 | N/A | -82 | N/A |
| 12/31/2015 | 62 | -60 | N/A | -65 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: BONEX 'nin tahmini kazanç büyümesi (yıllık 34.5% ) tasarruf oranının ( 2% ) üzerindedir.
Kazançlar ve Piyasa: BONEX şirketinin kazançlarının (yıllık 34.5% ) Swedish pazarından (yıllık 8.8% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: BONEX şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.
Gelir ve Pazar: BONEX şirketinin gelirinin (yıllık 23.7% ) Swedish pazarından (yıllık 0.04% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: BONEX şirketinin gelirinin (yıllık 23.7% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: BONEX 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 35.9 %)
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/21 10:59 |
| Gün Sonu Hisse Fiyatı | 2026/05/21 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Bonesupport Holding AB (publ) 8 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | ABG Sundal Collier |
| Erik Cassel | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |